HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Spanish Translation All Versions of this Article: 01.wnl.0000254483.19854.efv1 68/14/1141    most recent Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldwurm, S. Articles by Pezzoli, G. Search for Related Content PubMed PubMed Citation Articles by Goldwurm, S. Articles by Pezzoli, G. Related Collections Parkinson's disease/Parkinsonism All Genetics

Evaluation of LRRK2 G2019S penetrance

Relevance for genetic counseling in Parkinson disease

From Istituti Clinici di Perfezionamento (S.G., M.Z., S.T., F.S., G.P.), Parkinson Institute-Milan; Unit of Medical Statistics and Biometry (L.M., R.M.), Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan; Molecular Genetics Laboratory (F.S.), Foundation "Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena," Milan; Clinical Genetic Service (M.C.), Department of Pediatrics, University of Padova, Italy; and Department of Clinical Genetics (V.B.), Erasmus MC Rotterdam, The Netherlands.

Address correspondence and reprint requests to Dr. Stefano Goldwurm, Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126 Milan, Italy; e-mail: goldwurm{at}parkinson.it

We report the results of a family-based study of LRRK2 G2019S penetrance in Parkinson disease. We studied 19 families identified through the analysis of unrelated consecutive patients. The cumulative incidence of the disease was 15% at 60 years, 21% at 70 years, and 32% at 80 years. This study provides accurate estimates of G2019S penetrance by minimizing the selection bias.

This article was previously published in electronic format as an Expedited E-Pub on January 10, 2007, at www.neurology.org.

The "Human genetic bank of patients affected by PD and parkinsonisms" of the Parkinson Institute—Istituti Clinici di Perfezionamento, Milan (http://www.parkinson.it/dnabank.html) is supported by the Italian Telethon Foundation (grant no. GTF04007). Supported by the "Fondazione Grigioni per il Morbo di Parkinson" (award "Maria Vincenzina Grosso") to S. Goldwurm, and by the "Internationaal Parkinson Fonds" (The Netherlands) to V. Bonifati.

Disclosure: The authors report no conflicts of interest.

Received July 28, 2006. Accepted in final form November 13, 2006.

This article has been cited by other articles:

				D G Healy, N W Wood, and A H V Schapira Test for LRRK2 mutations in patients with Parkinson's disease Practical Neurology, December 1, 2008; 8(6): 381 - 385. [Abstract] [Full Text] [PDF]

				C. Marras and A. Lang Invited Article: Changing concepts in Parkinson disease: Moving beyond the Decade of the Brain Neurology, May 20, 2008; 70(21): 1996 - 2003. [Abstract] [Full Text] [PDF]